Francesca De Bacco

Francesca De Bacco

Auto-generated profile, based on publicly available information

Francesca De Bacco

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FOFrancesca Orzan
Francesca Orzan
FBFrancesca De Bacco
Francesca De Bacco
ELElisabetta Lazzarini
Elisabetta Lazzarini
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
AGAlessandra Gasparini
Alessandra Gasparini
CBCarla Boccaccio
Carla Boccaccio
Purpose: Current glioma diagnostic guidelines call for molecular profiling to stratify patients into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, cerebrospinal fluid (CSF) has been proposed as a reliable tumor DNA source for liquid biopsy. We prospectively investigated the use of CSF for molecular characterization of newly diagnosed gliomas. Experimental Design: We recruited two cohorts of newly diagnosed patients with glioma, one (n = 45) providing CSF collected in proximity of the tumor, the other (n = 39) CSF collected by lumbar puncture (LP). Both cohorts provided tumor tissues by surgery concomitant with CSF sampling. DNA samples retrieved from CSF and matched tumors were systematically characterized and compared by comprehensive (NGS, next-generation sequencing) or targeted (ddPCR, droplet digital PCR) methodologies. Conventional and molecular diagnosis outcomes were compared. Results: We report that tumor DNA is abundant in CSF close to the tumor, but scanty and mostly below NGS sensitivity threshold in CSF from LP. Indeed, tumor DNA is mostly released by cells invading liquoral spaces, generating a gradient that attenuates by departing from the tumor. Nevertheless, in >60% of LP CSF samples, tumor DNA is sufficient to assess a selected panel of genetic alterations (IDH and TERT promoter mutations, EGFR amplification, CDKN2A/B deletion: ITEC protocol) and MGMT methylation that, combined with imaging, enable tissue-agnostic identification of main glioma molecular subtypes. Conclusions: This study shows potentialities and limitations of CSF liquid biopsy in achieving molecular characterization of gliomas at first clinical presentation and proposes a protocol to maximize diagnostic information retrievable from CSF DNA.

3 September 2021 in Molecular & Cellular Oncology
Verified
Journal Article
Open access
FBFrancesca De Bacco
Francesca De Bacco
CBCarla Boccaccio
Carla Boccaccio
By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.


1 April 2023
Verified
Other
Open access
FOFrancesca Orzan
Francesca Orzan
FBFrancesca De Bacco
Francesca De Bacco
ELElisabetta Lazzarini
Elisabetta Lazzarini
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
AGAlessandra Gasparini
Alessandra Gasparini
CBCarla Boccaccio
Carla Boccaccio
Supplementary Figures 1-4, Supplementary Tables S1-S13, Description of Supplementary Data 1-3, Supplementary Materials and Methods, Supplementary References.